Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ironwood Pharmaceuti (NQ: IRWD ) 6.790 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Ironwood Pharmaceuti < Previous 1 2 3 4 5 6 Next > Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance January 08, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio December 12, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Earnings Preview For Ironwood Pharmaceuticals August 07, 2023 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga A Preview Of Ironwood Pharmaceuticals's Earnings February 14, 2024 Via Benzinga Chart Of The Day: Ironwood Pharma - Gastrointestinal Products February 13, 2024 Via Talk Markets Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call February 01, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation January 08, 2024 From Ironwood Pharmaceuticals, Inc. Via Business Wire Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management November 30, 2023 Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to... Via Newsfile Ironwood Pharmaceuticals to Participate in the Piper Sandler 35th Annual Healthcare Conference November 21, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Reports Third Quarter 2023 Results November 09, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call October 26, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting October 23, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition, a Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity (CIC) at United European Gastroenterology Week October 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old October 05, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 September 28, 2023 Via Benzinga Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session September 19, 2023 Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. Via Benzinga Orchestra BioMed, Vital Farms And Other Big Stocks Moving Higher On Tuesday September 19, 2023 U.S. stocks traded lower on Tuesday. Here are some big stocks recording gains in today’s session. Via Benzinga Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance August 08, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call July 25, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood and VectivBio Announce the Completion of the Tender Offer for VectivBio Shares June 29, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood and VectivBio Announce Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition of VectivBio June 16, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old June 12, 2023 From Ironwood Pharmaceuticals, Inc. Via Business Wire Down 7% in 2023, This Struggling Growth Stock Could Soon Make a Turnaround June 12, 2023 Ironwood's plan to purchase a smaller biotech should address some issues that have shareholders concerned. Via The Motley Fool The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree June 02, 2023 Big Pharma is facing a patent cliff that could siphon off billions in revenue. Via Investor's Business Daily Why Ironwood Pharmaceuticals Stock Bumped Higher Today May 22, 2023 Investors indicated approval of the company's upcoming $1 billion asset purchase. Via The Motley Fool Ironwood Scoops Up Gastrointestinal Diseases Player For $1B May 22, 2023 Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) has agreed to acquire VectivBio Holding AG (NASDAQ: VECT) for $17.00 per share in an all-cash transaction with an estimated aggregate consideration of... Via Benzinga Why Shares of VectivBio Holding Are Up Today May 22, 2023 A buyout offer by Ironwood Pharmaceuticals lifted the clinical-stage biotech's stock. Via The Motley Fool Merger Monday May 22, 2023 This morning, Chevron announced a deal to acquire PDC Energy for $72 per share in stock. Via Talk Markets < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.